Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 1 examiners • 0 of 3 (0%) have an AI response strategy ready
Revival Animal Health LLC currently has 3 pending office actions within its portfolio. These actions are situated in the Biotechnology & Pharmaceuticals technology area. The presence of 3 pending office actions indicates an active phase of patent prosecution for the company's technical innovations.
The prosecution landscape for this entity is highly centralized, with 1 distinct examiner and 1 distinct art unit handling all matters. The presence of 1 distinct examiner and 1 distinct art unit means that all 3 of the pending office actions are being reviewed by the same person. For practitioners, this centralization simplifies the prosecution process as it involves a point of contact within the patent office.
CLARKE, TRENT R is the busiest examiner for this company, overseeing 3 busiest examiner pending actions. These 3 busiest examiner pending actions represent the entirety of the company's 3 pending office actions. This means that CLARKE, TRENT R has total influence over the current outcomes for the company's filings in the Biotechnology & Pharmaceuticals area.
The concentration in 1 distinct art unit and under 1 distinct examiner allows for a very consistent prosecution strategy. Practitioners should focus on the specific examination style and previous rulings of CLARKE, TRENT R. The resolution of the 3 pending office actions will likely be governed by the same set of technical interpretations and administrative standards within this art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CLARKE, TRENT R | 3 | 42.0% | +24.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18909731 | SYSTEM AND METHOD FOR AGGREGATION AND AUTOLOGOUS USE OF ALPHA 2M MOLECULES TO TREAT RESPIRATORY CONDITIONS | CLARKE, TRENT R | — |
| 18909762 | SYSTEM AND METHOD FOR ALLOGENEIC OR XENOGENEIC USE OF ALPHA 2M MOLECULES IN TREATING MEDICAL CONDITIONS | CLARKE, TRENT R | — |
| 18215498 | SYSTEM AND METHOD FOR ISOLATING ALPHA 2M MOLECULES | CLARKE, TRENT R | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18909731 | SYSTEM AND METHOD FOR AGGREGATION AND AUTOLOGOUS USE OF ALPHA 2M MOLECULES TO TREAT RESPIRATORY CONDITIONS | CLARKE, TRENT R | — |
| 18909762 | SYSTEM AND METHOD FOR ALLOGENEIC OR XENOGENEIC USE OF ALPHA 2M MOLECULES IN TREATING MEDICAL CONDITIONS | CLARKE, TRENT R | — |
| 18215498 | SYSTEM AND METHOD FOR ISOLATING ALPHA 2M MOLECULES | CLARKE, TRENT R | — |
| Art Unit | Apps |
|---|---|
| 1651 | 3 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18909731 | SYSTEM AND METHOD FOR AGGREGATION AND AUTOLOGOUS USE OF ALPHA 2M MOLECULES TO TREAT RESPIRATORY CONDITIONS | CLARKE, TRENT R | 1651 | §103§112 | Final Rejection | — | Pending | Oct 08, 2024 |
| 18909762 | SYSTEM AND METHOD FOR ALLOGENEIC OR XENOGENEIC USE OF ALPHA 2M MOLECULES IN TREATING MEDICAL CONDITIONS | CLARKE, TRENT R | 1651 | §103§112 | Final Rejection | — | Pending | Oct 08, 2024 |
| 18215498 | SYSTEM AND METHOD FOR ISOLATING ALPHA 2M MOLECULES | CLARKE, TRENT R | 1651 | §103§112 | Final Rejection | — | Pending | Jun 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial